On Wednesday, Merck received approval to update its Cervical Cancer vaccine, Gardasil (protects against human papillomavirus). The updated version of Gardasil is Gardasil 9, named as such due to the fact that it protects against 9 strains of the human papillomavirus.
The original vaccine that was approved in 2006 only covered four strains; with this new "update", Gardasil nine has the potential to prevent around ninety percent of vaginal, anal, vulvar and cervical cancers according to the Food and Drug Administration.
Gardasil 9 has been approved for both sexes; for females, the ages are nine to twenty six, while for males the ages are nine to fifteen. Merck conducted studies on over 13,000 patients; vaccinations require three doses to be given over a period of six months. Some side effects (common ones) that were tied to the vaccine included swelling, pain and redness.
To read more: http://www.nytimes.com/2014/12/11/business/fda-approves-new-version-of-cervical-cancer-vaccine.html?_r=0